Curcumin (Turmeric)
Curcuma longa
The golden anti-inflammatory polyphenol.
Evidence tier
Moderate
Research weight
Citations
23 verified / 23
Classification
Ayurvedic
❝
What the evidence says. Graded moderate: bioavailability-enhanced curcumin eases osteoarthritis pain about as well as NSAIDs across several RCTs, but raw curcumin is barely absorbed, many trials are small, and umbrella reviews rate their methodological quality as poor — so confidence is capped despite consistent signals. (Moderate evidence: Several controlled trials; effects real but modest or context-dependent.)
What is Curcumin (Turmeric)?
Curcumin (Turmeric) (Curcuma longa) is an Ayurvedic herb used for joint pain relief. NutriDex grades the human evidence as Moderate. Curcumin is turmeric's principal active polyphenol with potent anti-inflammatory and antioxidant activity in vitro. Clinically, bioavailability-enhanced forms reduce osteoarthritis pain comparably to NSAIDs in several trials and lower inflammatory markers. Raw curcumin is poorly absorbed, so formulation matters greatly. Early data also suggest small antidepressant and metabolic benefits.
Purported Benefits
✓Joint pain relief
✓Anti-inflammatory
✓Antioxidant
✓Mood support
Evidence by outcome
The same supplement can be well-proven for one use and unproven for another — here is the human evidence graded outcome by outcome.
| Outcome | Evidence | Effect | Studies |
|---|---|---|---|
| Osteoarthritis / knee pain reliefMany RCT meta-analyses show bioavailability-enhanced curcumin cuts WOMAC/VAS pain ~30% and is non-inferior to NSAIDs, though underlying review quality is often poor. | Moderate | ↑ benefit · moderate | 6 |
| Anti-inflammatory (CRP/cytokines)Meta-analyses show lowered CRP/hs-CRP and TNF-alpha, strongest at <=1000 mg/day over >10 weeks; effect on IL-6/ESR/IL-1beta inconsistent. | Moderate | ↑ benefit · moderate | 4 |
| Depression / mood supportPooled RCTs show a modest antidepressant effect (SMD -0.32) and higher response, but authors rate overall evidence quality as low. | Preliminary | ↑ benefit · small | 2 |
| Anxiety reductionOne meta-analysis (8 RCTs) reported a large anxiety reduction (SMD -1.56) but with wide CIs and small heterogeneous trials. | Preliminary | ↑ benefit · moderate | 1 |
| Cardiometabolic markers (NAFLD/lipids/glucose)Umbrella/meta-analyses show modest improvements in liver enzymes, triglycerides, HOMA-IR, weight and glucose; effects small and plateau ~80 mg/day. | Moderate | ↑ benefit · small | 4 |
| Cognition in agingMeta-analysis of 10 RCTs found no significant effect on global cognition (SMD 0.14, CI crosses zero); only isolated domains benefited. | Mixed | — no effect · negligible | 1 |
| Liver injury (harm)NIH LiverTox and case reports document rare hepatocellular drug-induced liver injury, especially with high-dose or piperine-enhanced products. | Preliminary | ⚠ risk | 2 |
Dosing & Compounds
Typical Dose
500–1,000 mg curcuminoids/day; bioavailability-enhanced forms preferred.
Active Compounds
Safety & Cautions
Generally safe. High doses may cause GI upset. Can increase bleeding risk and interact with blood thinners. Rare but serious cases of turmeric/curcumin-associated liver injury have been documented (NIH LiverTox), with risk possibly higher for piperine-enhanced formulas; may also inhibit drug-metabolizing enzymes and reduce iron absorption. Educational only — always check with your doctor or pharmacist before combining Curcumin (Turmeric) with any medicine.
Curcumin (Turmeric) drug interactions
Known or theoretical interactions between Curcumin (Turmeric) and common medications — educational, not exhaustive. Always check with your doctor or pharmacist before combining Curcumin (Turmeric) with any medicine.
Monitor
Warfarin & antiplatelet drugs
High-dose curcumin/turmeric may increase bleeding risk with blood thinners.
Curcumin can inhibit platelet aggregation and may potentiate anticoagulant/antiplatelet effects. NIH NCCIH — Turmeric
Key Studies ★ 23 studies
Meta-analysis
Wang 2025 (meta-analysis)
✓ PubMed
Across 10 RCTs (786 patients), Curcuma longa significantly improved knee osteoarthritis pain vs placebo (VAS MD 18.25, 95% CI 7.79-28.72) and was non-inferior to NSAIDs on WOMAC total score.
Meta-analysis
Sun 2024 (anxiety meta-analysis)
✓ PubMed
Pooling 8 RCTs (567 participants), curcumin significantly reduced anxiety symptoms (SMD -1.56, 95% CI -2.48 to -0.64).
Systematic review
2025 ulcerative colitis meta-analysis
✓ PubMed
Across 8 RCTs (482 patients), adjunctive curcumin more than doubled clinical remission vs placebo (RR 2.33, 95% CI 1.25-4.34) with no serious adverse events.
Meta-analysis
Mansouri 2024 (NAFLD umbrella meta-analysis)
✓ PubMed
Umbrella analysis of 11 meta-analyses (99 RCTs, 5,546 participants) found curcumin/turmeric reduced AST, ALT, triglycerides, HOMA-IR, BMI and waist circumference in NAFLD, with no significant effect on LDL-C, total cholesterol, FBS or HbA1c.
Systematic review
2025 type 2 diabetes meta-review
✓ PubMed
Meta-review of 13 meta-analyses covering 63 RCTs (3,706 participants) found curcumin modestly lowered fasting blood glucose (-6.30 mg/dL) and HbA1c (-0.31%) in type 2 diabetes/hyperglycemia.
Meta-analysis
Yang 2023 (cardiometabolic dose-response meta-analysis)
✓ PubMed
Across 31 RCTs, curcumin produced modest reductions in body weight (-0.94 kg), BMI, LDL-C, total cholesterol and hs-CRP and raised HDL-C, with effects plateauing around 80 mg/day.
Meta-analysis
2025 rheumatoid arthritis meta-analysis
✓ Full text
Pooling 7 RCTs, curcumin meaningfully improved RA disease activity (DAS28 WMD -1.47) and lowered CRP and ESR, with no serious adverse events.
meta-analysis
Targeting cognitive aging 2025 (meta-analysis)
✓ PubMed
Pooling 10 human RCTs (531 participants), curcumin had no significant effect on global cognition versus placebo (SMD 0.14, 95% CI -0.78 to 1.07), with benefit seen only in specific domains such as working memory and processing speed.
Systematic review
Wang 2025
✓ PubMed
Network meta-analysis of 17 RCTs found all turmeric preparations significantly reduced WOMAC pain vs placebo; bioavailability-enhanced curcuminoids cut WOMAC pain ~30% (MD -2.47, 95% CI -3.27 to -1.67), reaching the minimal clinically important difference.
Systematic review
Chen 2025 (umbrella review)
✓ Full text
Critical umbrella review of intervention meta-analyses found that in osteoarthritis, Curcuma longa extract/curcumin reduced VAS pain and WOMAC pain, function and stiffness vs placebo and had effects on joint pain similar to NSAIDs, though overall methodological quality of underlying reviews was relatively poor.
Meta-analysis
Inflammatory biomarkers MA 2025
✓ PubMed
Meta-analysis of 21 RCTs (1705 knee OA patients) found curcumin significantly lowered serum CRP and TNF-alpha vs placebo, with no significant differences in ESR, IL-1beta, IL-6, or PGE-2.
Meta-analysis
Serum biomarkers MA (PMC) 2025
✓ Full text
Full-text systematic review and meta-analysis of randomized controlled trials confirming curcumin reduces serum CRP and TNF-alpha in knee osteoarthritis (21 studies, 1705 patients; databases searched to March 2025).
Systematic review
Frontiers SR/MA review 2025
✓ Full text
Critical review of systematic reviews and meta-analyses of curcumin for knee osteoarthritis synthesizing the evidence base and grading methodological quality of existing pooled analyses.
Meta-analysis
Zhao 2023 (Bayesian network meta-analysis)
✓ PubMed
Network meta-analysis of 23 RCTs (2175 knee OA patients): vs placebo, curcumin significantly reduced VAS pain (MD -1.63, 95% CI -2.91 to -0.45) and total WOMAC (MD -18.85, 95% CI -29.53 to -8.76), and lowered rescue-medication use (OR 0.17); curcumin had fewer adverse events than NSAIDs (OR 0.51).
meta-analysis
Heydari 2022 (PCOS meta-analysis)
✓ PubMed
Across 7 RCTs (447 women with PCOS), curcumin lowered fasting glucose, insulin, HOMA-IR, total cholesterol, CRP and BMI but had no significant effect on reproductive hormones (testosterone, DHEA, LH, FSH).
Meta-analysis
Feng 2022 (systematic review/meta-analysis)
✓ PubMed
15 RCTs (1670 patients): curcuminoids alone vs placebo improved VAS pain (WMD -1.77, 95% CI -2.44 to -1.09) and WOMAC total (WMD -7.06), function and stiffness; non-inferior to NSAIDs for pain/function with no increase in adverse events.
Meta-analysis
Gorabi 2021 (updated meta-analysis of RCTs)
✓ PubMed
Curcumin supplementation significantly lowered systemic inflammation markers vs placebo: CRP (WMD -3.67 mg/L, 95% CI -6.96 to -0.38; 9 studies) and hs-CRP (23 studies), with effect strongest at doses <=1000 mg/day and >10-week duration.
Meta-analysis
Wang 2020 (systematic review/meta-analysis)
✓ PubMed
10 RCTs (594 patients): curcumin significantly reduced depressive symptoms vs placebo (SMD -0.32, 95% CI -0.50 to -0.13) and increased response rates (OR 3.20, 95% CI 1.28-7.99), with drop-out/adverse-event rates comparable to placebo; authors rate overall evidence quality as low.
Meta-analysis
Daily 2016 meta-analysis
✓ PubMed
Reduced arthritis symptoms similarly to NSAIDs across 8 trials.
agency/authoritative reference
Turmeric - LiverTox (NIH) 2024
✓ Full text
NIH LiverTox monograph documents that turmeric/curcumin supplements, especially high-dose or piperine-enhanced products, can cause acute hepatocellular drug-induced liver injury, typically hepatocellular with autoimmune features and resolving after discontinuation.
case report
Cureus 2025 (turmeric-piperine DILI case report)
✓ PubMed
Case report of a 35-year-old man who developed jaundice, fatigue and pruritus from a turmeric supplement containing piperine, with liver tests normalizing and full recovery after discontinuation, illustrating curcumin-associated drug-induced liver injury.
Study
Sahebkar 2016
✓ PubMed
Lowered circulating inflammatory cytokines.
Study
Ng 2017
✓ PubMed
Modest antidepressant effect in pooled analysis.